Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Beware The Biotech Folly Of Self-Commercialization

Partnering A First Asset to Big Pharma Brings More Benefits Than Money

Executive Summary

If the lengthy litigation history is any guide, Amgen regretted licensing its first product to a big pharma partner, probably because the product was so successful. For most first products, however, a big pharmaceutical collaboration can bring many benefits but the converse – self-commercialization of the first product – has far fewer positive historical connotations.

You may also be interested in...



Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Zulresso Is Sage’s First Step In Postpartum Depression Treatment

I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.

'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel